Dr. Landgren Discusses MRD Detection for Multiple Myeloma

C. Ola Landgren, MD, PhD
Published: Wednesday, Nov 04, 2015



C. Ola Landgren, MD, PhD, hematologic oncologist, chief, Myeloma Service, Memorial Sloan Kettering Cancer Center, discusses minimal residual disease detection for progression-free survival (PFS) and overall survival (OS) for patients with multiple myeloma.

Several studies show that those who are MRD-negative often have a better PFS and OS compared with those who are MRD-positive, Landgren explains.

Similar to other disease types where MRD detection is used, Landgren says there is a gradient of sensitivity for these assays. For patients who are MRD-negative, less disease is detected.

<<< View more from the 2015 CFS Annual Meeting



C. Ola Landgren, MD, PhD, hematologic oncologist, chief, Myeloma Service, Memorial Sloan Kettering Cancer Center, discusses minimal residual disease detection for progression-free survival (PFS) and overall survival (OS) for patients with multiple myeloma.

Several studies show that those who are MRD-negative often have a better PFS and OS compared with those who are MRD-positive, Landgren explains.

Similar to other disease types where MRD detection is used, Landgren says there is a gradient of sensitivity for these assays. For patients who are MRD-negative, less disease is detected.

<<< View more from the 2015 CFS Annual Meeting




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and VomitingOct 31, 20182.0
Publication Bottom Border
Border Publication
x